Various studies have indicated that the genetic composition of two individuals is unlikely to be similar. This can be attributed to the fact that the genetic makeup of an individual is influenced by various factors, such as family history, as well as environmental and health conditions. Therefore, one treatment cannot be expected to be successful in every patient suffering from the same disorder. It is worth highlighting that the inability to report a health issue to a medical practitioner in its initial stage is expected to cost productivity losses worth over USD 40-90 billion, each year. Further, frequent hospitals visits can cause additional financial burden on patients. In order to mitigate the aforementioned challenges, healthcare professionals are shifting towards the use of personalized / precision medicine. This approach, as opposed to the one-size-fits-all approach, enables healthcare professionals to offer a precise treatment option for a specific disease that is likely to prove effective for a group of individuals. This domain has the ability to reduce treatment burden across many therapeutic areas including oncological disorders, rheumatology disorders.
Given the various advantages offered by precision medicine, healthcare organizations are gradually becoming more interested in adopting such solutions. Further, with the advent of bioinformatics and artificial intelligence tools, there has been a significant rise in the adoption of such applications. For instance, in June 2020, Infosys launched its proprietary personalized medicine solution, equipped with latest SAP S/4HANA® technology, to gain intelligent insights to deliver personalized experience to patients. It is worth highlighting that precision medicine software solutions are widely used by healthcare providers for the diagnosis, as well as prognosis, of the disease. However, the scope is being continuously expanded in order to include the prevention and recovery of life threatening diseases. At present, several software applications integrate clinical and diagnostic data, along with financial data, offering deeper and precise insights to healthcare providers, as well as helping them improve patient outcomes. Players engaged in the development of precision medicine software applications have observed a significant growth over the past few years. More than 120 software solutions have been developed and are available commercially. It is also worth highlighting that over USD 2 billion has been invested in this domain by various stakeholders in the last four years. As a result of the rising adoption and preference for precision medicine software applications, coupled to the ongoing efforts of software providers to further improve the current software solutions, we believe that the precision medicine software services market is likely to witness significant growth in the foreseen future.
The “Precision Medicine Software Developers Market by Target Therapeutic Indication (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders), Key Geographical Regions (North America, Europe, Asia-Pacific) and Types of End Users (Healthcare Providers, Research and Government Institutes, Pharmaceutical and Biotech Companies): Industry Trends and Global Forecasts, 2021-2031” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of precision medicine software in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
All actual figures have been sourced and analyzed from publicly available information forums and secondary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Given the various advantages offered by precision medicine, healthcare organizations are gradually becoming more interested in adopting such solutions. Further, with the advent of bioinformatics and artificial intelligence tools, there has been a significant rise in the adoption of such applications. For instance, in June 2020, Infosys launched its proprietary personalized medicine solution, equipped with latest SAP S/4HANA® technology, to gain intelligent insights to deliver personalized experience to patients. It is worth highlighting that precision medicine software solutions are widely used by healthcare providers for the diagnosis, as well as prognosis, of the disease. However, the scope is being continuously expanded in order to include the prevention and recovery of life threatening diseases. At present, several software applications integrate clinical and diagnostic data, along with financial data, offering deeper and precise insights to healthcare providers, as well as helping them improve patient outcomes. Players engaged in the development of precision medicine software applications have observed a significant growth over the past few years. More than 120 software solutions have been developed and are available commercially. It is also worth highlighting that over USD 2 billion has been invested in this domain by various stakeholders in the last four years. As a result of the rising adoption and preference for precision medicine software applications, coupled to the ongoing efforts of software providers to further improve the current software solutions, we believe that the precision medicine software services market is likely to witness significant growth in the foreseen future.
Scope of the Report
The “Precision Medicine Software Developers Market by Target Therapeutic Indication (Oncological Disorders, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders), Key Geographical Regions (North America, Europe, Asia-Pacific) and Types of End Users (Healthcare Providers, Research and Government Institutes, Pharmaceutical and Biotech Companies): Industry Trends and Global Forecasts, 2021-2031” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of precision medicine software in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
Amongst other elements, the report features the following:
- A detailed overview of the current market landscape of precision medicine software developers, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, types of platforms (cloud-based and on-premises), purpose of software (diagnosis, analysis, treatment), type of data (genomic data, clinical data, image data and others), therapeutic area (oncological disorders, cardiovascular disorders, neurological disorders, metabolic disorders) and types of end users (healthcare providers, research and government institutes, pharmaceutical and biotech companies).
- Elaborate profiles of key players engaged in the development of precision medicine software applications. Each profile features a brief overview of the company, along with its information on technology / service portfolio, recent developments and an informed future outlook.
- A detailed analysis of the various patents that have been filed / granted within this domain, since 2018. It highlights the key trends associated with these patents across several relevant parameters, such as publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, type of organization, leading patent assignees and most active players (in terms of number of patents filed). In addition, it includes a patent benchmarking analysis and patent valuation.
- An analysis of the recent partnerships inked between various players engaged in this domain, during the period 2018-2021, based on several relevant parameters, such as year of partnership, type of partnership model adopted, regional distribution (continent and country-wise) and most active players (in terms of number of partnerships inked).
- A detailed analysis of various investments made by players engaged in this domain, based on several relevant parameters such as year of investment, number of funding instances, amount invested and type of funding (venture capital financing, debt financing, grants / awards, initial public offering (IPO)) undertaken by companies engaged in this domain, during the period 2018-2021.
- A detailed analysis based on a proprietary 2×2 representation, highlighting the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
- A detailed discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, along with a Harvey ball analysis.
All actual figures have been sourced and analyzed from publicly available information forums and secondary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- Who are the key players engaged in the development of precision medicine software applications?
- Which type of platform is more likely to outreach the market in the near future?
- Which companies are actively engaged in the development of precision medicine software applications?
- What are the major therapeutic areas targeted by various precision medicine software applications?
- What kind of partnership models are commonly adopted by industry stakeholders?
- Who are the key investors in this domain?
- Who are the target users of precision medicine software applications?
- What are the different types of data being handled by precision medicine software developers?
- What is the main purpose for using precision medicine software applications?
- How is the current and future opportunity likely to be distributed across key market segments?
Table of Contents
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE
5. COMPANY PROFILES
6. COMPANY COMPETITIVENESS ANALYSIS
7. PATENT ANALYSIS
8. PARTNERSHIPS AND COLLABORATIONS
9. FUNDING AND INVESTMENT ANALYSIS
10. ATTRACTIVENESS COMPETITIVENESS MATRIX
11. MARKET FORECAST
12. SWOT ANALYSIS
Companies Mentioned
- 2bPrecise
- 2nd.MD
- 4D Path
- 83North
- AB Enzymes
- Abu Dhabi Health Data Services
- ACE & Company
- AceTech
- Admera Health
- Advaita
- AdventHealth
- Adventist Health
- Aetna
- AG Mednet
- Agilent Technologies
- Ainnova Tech
- AIQ Solutions
- Alexandria Venture Investments
- AliveAndKickn
- Allscripts
- Ally Bridge Group
- Altis Labs
- Altium Capital
- Alychlo
- AMedSU
- American Heart Association
- American Society of Clinical Oncology
- Amgen
- AMITA Health
- aMoon
- AMRA Medical
- PathWest Laboratory Medicine
- ARCH Venture Partners
- Ariel Precision Medicine
- ARUP Laboratories
- Ascension Ventures
- Asset Management Ventures
- Astarte Medical
- AstraZeneca
- ATW Partners
- Audacy
- Australian BioCommons
- Australian Research Data Commons (ARDC)
- Axiom Associates
- Babylon Health
- Baillie Gifford
- Bain Capital Ventures
- Bainbridge Health
- Balderton Capital
- Barts Health NHS Trust
- Bayer
- BC Platforms
- Beacon Capital
- Belgian Society of Medical Oncology
- BenevolentAI
- Biocept
- BioVariance
- Blueprint Medicines
- Boehringer Ingelheim Venture Fund
- Brainomix
- Breakthrough Genomics
- Briban Invest
- Bristol Myers Squibb
- Broad Institute
- Business Development Bank of Canada
- C2i Genomics
- Caesar
- Apple
- Cancer Genetics
- CancerIQ
- Capital Midwest Fund
- Caris Life Sciences
- Casdin Capital
- Catipult.AI
- Clayton, Dubilier & Rice (CD&R)
- Celgene
- Centana Growth Partners
- CENTOGENE
- Centro Hospitalar Lisboa Ocidental
- Cergentis
- Children’s Brain Tumor Tissue Consortium
- Chimera Partners
- Cigna Ventures
- Circle Cardiovascular Imaging
- Claremont Creek Ventures
- Cofactor Genomics
- Cohesic
- Colle Capital
- Color
- Community Health Network
- ConCR
- Connect Ventures
- Cornerstone Specialty Network
- Cortex
- Crohn’s & Colitis Foundation
- CureMatch
- Curii
- Data4Cure
- Datavant
- Decentralized Trials & Research Alliance
- Dell Technologies
- Diagnomics
- Diagnostic Laboratory Services
- Dian Diagnostics
- Discovery Life Sciences
- DNA Compass
- DNAnexus
- Dolby Family Ventures
- DoseMe (Acquired by Tabula Rasa HealthCare)
- DrChrono
- Driehaus Capital Management
- Duquesne Family Office
- Echo Health Ventures
- Eiffel Investment
- Elekta
- Elysia Capital
- Emory Healthcare
- Endeavour Vision
- e-NIOS
- EnvoyAI
- Epic App Orchard
- EpigeneticsRx
- Esplanade Ventures
- Essen University
- Eurazeo
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Specialist Investment
- EW Healthcare Partners
- Fabric Genomics
- Famille C Invest
- Farsight Genome Systems
- Feist-Weiller Cancer Center
- First Round Capital
- Flatiron Health
- Fluidigm
- Flywheel
- Foresite Capital
- Foundation Medicine
- F-Prime Capital
- Franklin Templeton
- Friends of Cancer Research
- GE Healthcare
- Geisinger
- Genedata
- General Catalyst
- Generation Investment Management
- Genetic Alliance
- Genetic Technologies
- GeneXplain
- Genmab
- Genome Medical
- GenomOncology
- Genomelink
- Genomenon
- Genomics England
- Genomind
- GenomOncology
- GenomSys
- Genospace
- GenXys Health Care Systems
- Gilead Sciences
- GNS Healthcare
- Golden Helix
- Green Shield Canada
- GreenM
- GV
- Hamilton Health Sciences
- Healix
- Health Catalyst Capital
- Health Innovation Manchester
- Healthgen AI
- HealthQuad
- Hearst Health
- Heritas Capital
- Highmark Health
- Hitachi
- Hôpital Foch
- Houston Methodist
- Huami
- HudsonAlpha Institute
- Human Longevity
- Hygea Precision Medicine
- Hyperfine
- Ibex Medical Analytics
- IBM
- International Development Association (IDA)
- Idinvest Partners
- iGlobe Partners
- Illumina
- Illumina Ventures
- Imaging Biometrics
- Imaginostics
- ImmunityBio
- Indiana Clinical and Translational Sciences Institute
- Indiana University
- Industrifonden
- iNDX.Ai
- InformedDNA
- Innovatus Capital Partners
- Inova Health System
- InsightRX
- Inspirata
- Integrated DNA Technologies
- Intellihealth
- Interactive Biosoftware
- Intermountain Healthcare
- Intero Life Sciences
- Intertrust Technologies
- IntrinsiQ Specialty Solutions
- IQVIA
- IRA Capital
- Janssen
- JDRF
- JiNan Danjier
- Kamet Ventures
- Kinship
- Koninklijke Philips
- Konyang University Hospital
- Kura Oncology
- LabCorp
- Lifebit
- LifeOmic Health
- Livongo
- LSS
- LunaPBC
- M2Gen
- MacroGenics
- Marienhaus Hospital
- Mary Crowley Cancer Research
- Mayo Clinic
- McKesson Ventures
- medASTUTE
- Medfusion
- Medical University of South Carolina
- Medidata
- MedImpact
- Medimsight
- Medipredict
- Medley Genomics
- Merck
- Merck Global Health Innovation Fund
- Merstal
- Merus
- Metabolon
- Microsoft
- MidCap Financial
- MindX Sciences
- Mission Bio
- Moffitt Cancer Center
- Molecular Health
- MolecularMatch
- MTIP
- Multiple Myeloma Research Foundation
- Murfreesboro Medical Clinic & SurgiCenter
- mymo.AI
- Myriad Genetics
- NantHealth
- NantOmics
- Nashville Veterans Affairs Hospital
- Natera
- National Cancer Center
- National Cancer Institute
- National Institute of Health
- NeoGenomics
- New Enterprise Associates
- Nextrans
- NFX
- NHS
- National Instruments (NI)
- National Institutes of Health (NIH)
- Nimbus Synergies
- Northpond Ventures
- NorthShore University HealthSystem
- Northwell Health
- Northwest Firefighters Benefits Trust
- Notable
- Novartis
- Novo Holdings
- NovogeneAIT Genomics
- NYU Grossman School of Medicine
- Octopus Ventures
- Ohio State University
- Olea Medical
- Oncora Medical
- OncXerna Therapeutics
- OneOncology
- Oracle
- Orion Health
- Osage University Partners
- Outcomes4Me
- Oxford University
- Pancreatic Cancer Action Network
- Paragon Genomics
- Parexel
- Parkwalk Advisors
- Pentech Ventures
- Perceiv AI
- Perceptive Advisors
- Personal Genome Diagnostics
- Pfizer
- Pharmatics
- PhenoTips®
- Phillips
- Phosphorus
- PierianDx
- Pillar Biosciences
- Pinnacle
- PipelineRx
- Planven Entrepreneur Ventures
- Precision Digital Health
- Precision for Medicine
- Precision Health Informatics
- Precision Health Software
- Premier
- Preon Capital
- Prisma Health
- Proscia
- Prudential Financial
- Psyche Systems
- Psychiatry-UK
- Pygar
- Q² Solutions
- QIAGEN
- Qlucore
- QMENTA
- QNA Dx
- Quadria Capital
- Quantgene
- QUBIS
- Quest Diagnostics
- Qynapse
- Renalytix AI
- Renown Health
- RetInSight
- Revelation Alpine
- Revolution Growth
- Roche
- Rock River Capital Partners
- 30Ventures
- RTI International
- Russell Microcap Index
- RxGenomix
- RXVIP Concierge
- Safeguard Scientifics
- San Francisco Otolaryngology
- Sanford Health
- Sano Genetics
- Sanofi
- SAP
- SCA Robotics
- ScienceVision
- ScreenPoint Medical
- Section 32
- Sentieon
- Seoul National University Hospital
- Sequoia
- Seven Bridges
- Sidney Kimmel Cancer Center
- Siemens Healthineers
- Sierra Ventures
- SimplicityBio
- SJF Ventures
- Social Capital
- SocialGenomics
- Sonraí Analytics
- SOPHiA GENETICS
- Spanish Lung Cancer
- St. Joseph’s/Candler
- St. Jude Children's Research Hospital
- Stanford Health Care
- Stone Checker
- Strand Life Sciences
- Stryker
- Studio Management
- Sun Life
- Sunquest Information Systems
- Susman Ventures
- Sutter Health
- Swisscom Ventures
- Syapse
- T. Rowe Price
- Tabula Rasa HealthCare
- Takeda
- Taliaz
- Teamsters
- TeamViewer
- Techstart Ventures
- Teladoc Health
- TELUS Ventures
- Tempus Labs
- Ten Coves Capital
- TeraRecon
- Terumo
- The Mark Foundation for Cancer Research
- Parker Institute
- Thermo Fisher Scientific
- Thomas Jefferson University
- TIGAR Health Technologies
- Tiger Global Management
- Tiny VC
- Tmunity Therapeutics
- Topcon Healthcare
- TPG Biotech
- Translational Sciences Institute
- Translational Software
- Trapelo Health
- Trialbee
- TriCore Reference Laboratories
- Triesta Sciences
- TwinStrand Biosciences
- Twist Bioscience
- Tydo
- UK Research and Innovation
- uMETHOD
- UnitedHealthcare
- University Hospital of Augsburg
- University of California
- University of Chicago
- University of Missouri Health Care
- University of Pittsburgh Medical Center (UPMC)
- US Orthopedic Alliance
- Vanderbilt-Ingram Cancer Center
- Vanderbilt University Medical Center
- Varian
- Verily Life Sciences
- Vicinity
- Vidence
- VigiLanz
- Viking Global Investors
- Visiopharm
- Welfare Fund of Philadelphia
- Wellcome Sanger Institute
- Wisconsin Investment Partners
- Genuity Science (formerly known as WuXi NextCODE)
- XIFIN
- Y Combinator
- YouScript
- Zero Childhood Cancer
- ZS Associates
Methodology
LOADING...
